Strategic Focus Target pediatric CNS disorders with disease-modifying, one-time gene therapies and cell-selective targeting, presenting a compelling value proposition for partnerships with hospitals, clinics, and patient foundations focusing on SCN1A+ Dravet syndrome and related epileptic encephalopathies.

Clinical Momentum Recent clinical data presentations at ASGCT 2026 for POLARIS Phase 1/2 trials and ongoing Dravet syndrome programs indicate near-term engagement opportunities with investigators, KOLs, and investigators seeking novel gene therapy approaches.

Regulatory & Safety Strong emphasis on safety and tolerability evidenced by NHP data and dose-expression control across brain regions, offering a differentiator for payers and clinical partners prioritizing risk-adjusted pathways and faster translation timelines.

Strategic Partnerships Providence for collaboration with patient advocacy groups (e.g., Dravet communities), CROs, and biotech financers given history of community engagement programs and a sizable Series D funding, enabling co-development and joint patient access programs.

Commercial Readiness Revenue scale and funding position enable discussions around access programs, manufacturing partnerships, and delivery system collaborations to support scalable global deployment once therapies reach late-stage validation.